IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening With C. elegans

IBI Feature: Accelerating Drug Discovery for Diseases of Ageing: In Vivo High Throughput Screening With C. elegans

In a most recent article in International Biopharmaceutical Industry, our CSO Prof David Weinkove explores how the nematode C. elegans is transforming drug discovery for age-related diseases.

The piece highlights the benefits of using C. elegans for high throughput screening (HTS), including scalability, cost-effectiveness, and human translatability.

Discover how advancements in HTS and AI are accelerating the development of treatments and read about successful case studies demonstrating the potential of C. elegans. The original article can be read here.

In an era where rapid drug discovery is crucial, high throughput screening (HTS) emerged in the 1990s as a significant development, allowing for the swift and effective identification of active compounds and deeper insights into biological pathways.

Read more from Magnitude Biosciences